CoChat

Progress on ocular siRNA gene‐silencing therapy and drug delivery systems

Jiang, Jinjin, Zhang, Xinru, Tang, Yue, Li, Shuhan, Chen, Jing · 2021 · Fundamental & Clinical Pharmacology
Cited by 54

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Age‐related macular degeneration (AMD) and glaucoma are global ocular diseases with high blindness rate. RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF‐04523655 for AMD, and SYL040012 and QPI‐1007 for glaucoma. Administration routes and vectors of gene drugs affect their therapeutic effect. Compared with the non‐viral vectors, viral vectors have limited payload capacity and potential immunogenicity. This review summarizes the progress of the ocular siRNA gene‐silencing therapy by focusing on siRNA drugs for AMD and glaucoma already used in clinical research, the main routes of drug delivery and the non‐viral vectors for siRNA drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/fcp.12561

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 111

  1. 10.1186/s12967-016-1101-8 · DOI · Paper page
  2. 10.4014/jmb.1711.11025 · doi:10.4014/jmb.1711.11025
  3. 10.1016/j.jconrel.2012.05.005 · DOI
  4. 10.1021/acsami.6b16689 · DOI · Paper page
  5. 10.1016/j.ejpb.2009.04.001 · DOI
  6. 10.1007/s11095-013-0971-1 · DOI
  7. 10.1016/S0169-409X(01)00193-4 · DOI · Paper page
  8. 10.1016/j.ejpb.2005.01.009 · DOI · Paper page
  9. Barar J., 2009, Ocular drug delivery; impact of in vitro cell culture models, J. Ophthalmic Vis. Res., 4, 238
  10. 10.1016/j.addr.2006.07.024 · DOI · Paper page
  11. 10.1007/BF02569055 · DOI · Paper page
  12. 10.1517/14712598.3.1.45 · DOI · Paper page
  13. 10.1016/j.ijpharm.2017.07.065 · DOI
  14. 10.1016/S1773-2247(14)50021-4 · DOI
  15. 10.4155/tde.12.94 · DOI
  16. 10.1007/s12668-016-0219-8 · DOI
  17. 10.1007/s11095-009-0042-9 · DOI
  18. 10.1016/j.ijpharm.2017.04.010 · DOI
  19. 10.1007/s13346-016-0335-6 · doi:10.1007/s13346-016-0335-6
  20. 10.1016/j.addr.2006.07.023 · DOI
  21. 10.1016/j.addr.2017.07.002 · DOI
  22. 10.1093/ageing/21.3.168 · doi:10.1093/ageing/21.3.168
  23. 10.1081/DDC-120002997 · DOI · Paper page
  24. 10.1371/journal.pone.0026103 · DOI
  25. 10.1111/jphp.12132 · DOI
  26. 10.1109/TUFFC.2013.2538 · DOI
  27. 10.1016/j.ultrasmedbio.2011.07.010 · DOI
  28. 10.1080/08820530902802161 · DOI
  29. 10.1016/j.ejps.2012.11.009 · DOI
  30. 10.1080/02713683.2019.1565890 · DOI · Paper page
  31. 10.1023/A:1023238530504 · DOI
  32. 10.1016/j.exer.2019.107711 · DOI · Paper page
  33. 10.4155/tde.11.20 · DOI
  34. 10.1136/bjophthalmol-2014-305252 · DOI · Paper page
  35. 10.2174/156720181101140212165729 · doi:10.2174/156720181101140212165729
  36. 10.1016/B978-0-8155-2025-2.10007-1 · DOI
  37. 10.1016/j.addr.2006.07.026 · DOI · Paper page
  38. 10.1088/0957-4484/20/50/505101 · DOI · Paper page
  39. 10.1007/s00018-018-2843-7 · DOI
  40. 10.1016/j.mam.2012.03.009 · DOI · Paper page
  41. 10.1016/j.arr.2009.01.001 · DOI
  42. 10.1111/j.1755-3768.2011.02179.x · DOI · Paper page
  43. 10.1016/j.mam.2012.04.006 · DOI
  44. 10.3109/09273948.2011.628432 · DOI · Paper page
  45. 10.1097/IAE.0b013e3181ad2341 · doi:10.1097/iae.0b013e3181ad2341
  46. 10.1016/S0002-9440(10)64525-7 · DOI · Paper page
  47. 10.1038/eye.2012.106 · DOI
  48. 10.1136/bjo.80.4.363 · DOI · Paper page
  49. 10.1136/bjo.81.2.154 · DOI · Paper page
  50. 10.4137/OED.S4878 · DOI · Paper page
  51. Dejneka N.S., 2008, Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes, Mol. Vis., 14, 997
  52. 10.1097/00006982-200402000-00018 · DOI · Paper page
  53. Kwak N., 2000, VEGF is major stimulator in model of choroidal neovascularization, Invest. Ophthalmol., 41, 3158
  54. 10.1038/380439a0 · DOI · Paper page
  55. 10.1038/sj.gt.3302641 · DOI · Paper page
  56. 10.1038/nm0603-669 · DOI · Paper page
  57. 10.5483/BMBRep.2006.39.5.469 · DOI · Paper page
  58. 10.1016/j.ajo.2010.02.006 · DOI · Paper page
  59. 10.1167/iovs.04-0052 · DOI · Paper page
  60. 10.1167/iovs.13-13449 · DOI
  61. 10.1167/iovs.13-12716 · DOI · Paper page
  62. 10.2174/1874364101004010052 · DOI · Paper page
  63. 10.1038/mt.2013.216 · DOI
  64. Wax M.B., 1987, Distribution and properties of beta adrenergic receptors in human iris/ciliar body, Invest. Ophthalmol. Vis. Sci., 28, 420
  65. 10.1089/jop.1990.6.143 · doi:10.1089/jop.1990.6.143
  66. 10.1136/bjo.66.12.788 · doi:10.1136/bjo.66.12.788
  67. Gonzalez V., 2014, Phase 2 of bamosiran (SYL040012), a novel RNAi based compound for the treatment of increased intraocular pressure associated to glaucoma, Investig. Ophthalmol. Vis. Sci., 55, 564
  68. Gonzalez V., 2016, Results of phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma, Assoc. Res. Vis. Ophthalmol., 57, 3023
  69. 10.3129/i07-046 · doi:10.3129/i07-046
  70. 10.2174/157015908784533851 · DOI
  71. 10.1038/cddis.2011.54 · DOI · Paper page
  72. 10.1007/s11095-017-2134-2 · DOI · Paper page
  73. 10.1089/nat.2014.0489 · DOI · Paper page
  74. 10.1016/j.drudis.2007.11.002 · DOI · Paper page
  75. 10.1016/j.jconrel.2015.12.012 · DOI · Paper page
  76. 10.4155/tde.11.20 · DOI
  77. 10.3390/pharmaceutics11100547 · DOI
  78. 10.1158/0008-5472.CAN-08-2428 · DOI · Paper page
  79. 10.1038/sj.gt.3302777 · DOI · Paper page
  80. 10.1200/JCO.2013.55.0376 · DOI · Paper page
  81. 10.1016/j.biotechadv.2019.04.012 · DOI · Paper page
  82. 10.1002/jcph.1480 · DOI · Paper page
  83. 10.1007/s00415-019-09602-8 · DOI
  84. 10.1002/mabi.201000302 · DOI
  85. 10.1021/bc800451j · DOI
  86. 10.1007/s10118-015-1632-0 · DOI
  87. 10.1002/mabi.201600051 · DOI
  88. 10.1039/b900880b · DOI · Paper page
  89. 10.1016/j.addr.2006.03.007 · DOI · Paper page
  90. 10.1002/wnan.1233 · DOI
  91. 10.1023/A:1007552007765 · DOI · Paper page
  92. 10.1016/j.biomaterials.2012.02.041 · DOI
  93. 10.1002/jps.21079 · DOI · Paper page
  94. 10.1039/C1NJ20408D · DOI
  95. 10.1111/jphp.12104 · DOI · Paper page
  96. 10.1016/j.ijpharm.2016.07.031 · DOI
  97. Wu J., 2013, Dendrimers as carriers for siRNA delivery and gene silencing: a review, Sci. World J., 2013, 1, 10.1155/2013/630654 · DOI
  98. 10.1039/c0jm03030a · DOI
  99. 10.1016/j.msec.2019.110245 · DOI
  100. Arranz‐Romera A., 2018, Simultaneous co‐delivery of neuroprotective drugs from multi‐loaded PLGA microspheres for the treatment of glaucoma, J. Control Release, 2019, 26
  101. 10.1016/j.jconrel.2012.01.043 · DOI · Paper page
  102. 10.1016/j.drudis.2019.02.001 · DOI · Paper page
  103. 10.1016/j.jconrel.2007.11.017 · DOI
  104. 10.1016/j.biomaterials.2010.07.082 · DOI · Paper page
  105. 10.1016/j.bbrc.2017.05.103 · DOI
  106. 10.1167/iovs.07-1077 · DOI · Paper page
  107. 10.1038/sj.gt.3302071 · DOI · Paper page
  108. 10.1039/C7NR03142D · DOI · Paper page
  109. 10.1111/jphp.12940 · DOI
  110. 10.1038/sj.mt.6300324 · DOI · Paper page
  111. 10.1002/smll.201803239 · DOI

Cited by

See all 54

Metadata

Authors
Jiang, J., Zhang, X., Tang, Y., Li, S., & Chen, J.
Venue
Fundamental & Clinical Pharmacology
Publisher
Wiley
Published
2020-05-08
Volume
35
Issue
1
Pages
4-24
ISSN
  • 0767-3981 (ISSN-L)
  • 1472-8206
OpenAlex
W3016941443
Cited by
54
References
17
FWCI
2.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.